期刊文献+

Fertility Care Provided by a Public Health Hospital to Viral-Infected Couples: A Case-Control Study

Fertility Care Provided by a Public Health Hospital to Viral-Infected Couples: A Case-Control Study
下载PDF
导出
摘要 <strong>Objective:</strong> <span><span><span style="font-family:"">To evaluate the results of ART (clinical pregnancies and baby home rates) in couples infected with HBV, HCV, HIV <span>or</span> mixed in a Referral <span>center</span>.</span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><b><span style="font-family:"">Patients: </span></b></span></span><span><span><span style="font-family:"">The study is a retrospective case-control study comprising <span>1587 cycles/1064 couples in the control group and 237 cycles/164 couples in the infected group, submitted to <i>in vitro</i> fertilization, intracytoplasmic sperm injection <span>and</span> embryo transfer. Two branches from the infected group were created: the HIV subgroup, comprising couples with one or both partners infected with HIV-1 (84 cycles/67 couples), and the HCV subgroup,</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><span style="font-family:"">including at least one partner infected with HCV (45 cycles/29 couples).<b> Results: </b>The infected group presented higher infertility duration (<i>P</i> < 0.001) and so did the HCV subgroup (<i>P</i> < 0.001). Tubal infertility was increased in the infected group (<i>P</i> < 0.001), and in the HIV (<i>P</i> < 0.001) and HCV (<i>P</i> = 0.01) subgroups. Oocytes and oocytes in metaphase II numbers were lower in the infected group, but not in the HIV and HCV subgroups. <span>Clinical</span> pregnancy rate was lower in the infected group (25.74%) when compared to</span></span></span><span><span><span style="font-family:""> the </span></span></span><span><span><span style="font-family:"">control</span></span></span><span><span><span style="font-family:""> (34.66%), probably due to the contribution of H</span></span></span><span><span><span style="font-family:"">CV individuals (17.78%), but not of HIV (28.57%). <span>Baby</span> home rate was lower in the infected group (21.52%) relative to the control group (28.42%), but no differences were found in the HIV (27.38%) and HCV (15.56%) subgroups.<b> Conclusions:</b> Despite the low clinical pregnancy rate in the HCV subgroup, baby home rates did not change from control. These data seem promising for couples with viral infections who wish to conceive.</span></span></span> <strong>Objective:</strong> <span><span><span style="font-family:"">To evaluate the results of ART (clinical pregnancies and baby home rates) in couples infected with HBV, HCV, HIV <span>or</span> mixed in a Referral <span>center</span>.</span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><b><span style="font-family:"">Patients: </span></b></span></span><span><span><span style="font-family:"">The study is a retrospective case-control study comprising <span>1587 cycles/1064 couples in the control group and 237 cycles/164 couples in the infected group, submitted to <i>in vitro</i> fertilization, intracytoplasmic sperm injection <span>and</span> embryo transfer. Two branches from the infected group were created: the HIV subgroup, comprising couples with one or both partners infected with HIV-1 (84 cycles/67 couples), and the HCV subgroup,</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><span style="font-family:"">including at least one partner infected with HCV (45 cycles/29 couples).<b> Results: </b>The infected group presented higher infertility duration (<i>P</i> < 0.001) and so did the HCV subgroup (<i>P</i> < 0.001). Tubal infertility was increased in the infected group (<i>P</i> < 0.001), and in the HIV (<i>P</i> < 0.001) and HCV (<i>P</i> = 0.01) subgroups. Oocytes and oocytes in metaphase II numbers were lower in the infected group, but not in the HIV and HCV subgroups. <span>Clinical</span> pregnancy rate was lower in the infected group (25.74%) when compared to</span></span></span><span><span><span style="font-family:""> the </span></span></span><span><span><span style="font-family:"">control</span></span></span><span><span><span style="font-family:""> (34.66%), probably due to the contribution of H</span></span></span><span><span><span style="font-family:"">CV individuals (17.78%), but not of HIV (28.57%). <span>Baby</span> home rate was lower in the infected group (21.52%) relative to the control group (28.42%), but no differences were found in the HIV (27.38%) and HCV (15.56%) subgroups.<b> Conclusions:</b> Despite the low clinical pregnancy rate in the HCV subgroup, baby home rates did not change from control. These data seem promising for couples with viral infections who wish to conceive.</span></span></span>
作者 Sofia Figueiredo Sónia Correia Graça Pinto Teresinha Simões Sofia Figueiredo;Sónia Correia;Graça Pinto;Teresinha Simões(Maternidade Dr. Alfredo da Costa, Nova Medical School, Lisbon, Portugal)
出处 《Open Journal of Obstetrics and Gynecology》 2021年第8期1013-1025,共13页 妇产科期刊(英文)
关键词 Viral Infections (HIV HBV and HCV) ART Viral Infections (HIV HBV and HCV) ART
  • 相关文献

参考文献1

二级参考文献48

  • 1Grazia Tosone,Alberto Enrico Maraolo,Silvia Mascolo,Giulia Palmiero,Orsola Tambaro,Raffaele Orlando.Vertical hepatitis C virus transmission:Main questions and answers[J].World Journal of Hepatology,2014,6(8):538-548. 被引量:5
  • 2Chun-Yan Yeung,Hung-Chang Lee,Wai-Tao Chan,Chun-Bin Jiang,Szu-Wen Chang,Chih-Kuang Chuang.Vertical transmission of hepatitis C virus: Current knowledge and perspectives[J].World Journal of Hepatology,2014,6(9):643-651. 被引量:6
  • 3A. H. Talal,J. LaFleur,R. Hoop,P. Pandya,P. Martin,I. Jacobson,J. Han,E. J. Korner.Absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV ‐infected, evaluated patients[J]. Aliment Pharmacol Ther . 2013 (4)
  • 4European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology . 2011
  • 5European Association for the Study of the Liver.EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatology . 2015
  • 6Sulkowski MS,Gardiner DF,Rodriguez-Torres M,et al.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. The New England Journal of Medicine . 2014
  • 7European Medicines Agency-Science Medicine Healts.Harvoni summary of product characteristics. http//www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/003850/WC500177995.pdf . 2015
  • 8Food and Drug Administration,U.S.National Library of Medicine,National Center for Biotechnology Information.Compound Summary for CID 86291595 Viekira Pak. http//pubchem.ncbi.nlm.nih.gov/compound/86291595 . 2015
  • 9European Medicines Agency-Science Medicine Healts.Olysio summary of product characteristics. http//www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002777/WC500167867.pdf . 2015
  • 10European Medicines Agency-Science Medicine Healts.Daklinza summary of product characteristics. http//www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/003768/WC500172848.pdf . 2015

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部